Form 4: Inhibitor Therapeutics Director Michelle Yanez Acquires 50,000 Shares of Common Stock

Director Michelle Yanez acquired 50,000 shares of Inhibitor Therapeutics common stock on April 1, 2024, as compensation under the company's 2014 Equity Incentive Plan.

Summary

• On April 1, 2024, Michelle Yanez, a director of Inhibitor Therapeutics, Inc. (INTI), acquired 50,000 shares of common stock.
• The acquisition was made as compensation pursuant to the Issuer's 2014 Equity Incentive Plan.
• The price per share was $0.
• Following the transaction, Yanez beneficially owns 896,271 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by a company director as part of an existing compensation plan. There's no indication of significant positive or negative implications.

Positives

• The acquisition of shares by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions and is a common occurrence for publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's continued investment in the company.

Key Dates

Keywords

Inhibitor Therapeutics, INTI, Michelle Yanez, Director, Common Stock, Equity Incentive Plan, Beneficial Ownership, SEC Form 4